Orris

GIVE THE TOPICS WHICH ARE MISSING IN THE SLIDE I AM APG SCHOLAR FOR PRESENTING IN INTERNATINAL SEMINAR INVOVING HOD OF THE DEPT ASSISTANT PROFFESSOR PROFFESSOR SUBJECT EXPERTS PG SCHOLARS

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

GIVE THE TOPICS WHICH ARE MISSING IN THE SLIDE I AM APG SCHOLAR FOR PRESENTING IN INTERNATINAL SEMINAR INVOVING HOD OF THE DEPT ASSISTANT PROFFESSOR PROFFESSOR SUBJECT EXPERTS PG SCHOLARS

Reading File
Reading File
Reading File
Searching the Web

preeclampsia international guideline prevention diagnosis management 2025 ACOG ISSHP NICE

Searching PubMed

preeclampsia AND guideline

Browsing Directory

~/

Browsing Directory

~/attachments/28839604-0248-42f6-8057-0ee7a14cfabb

Running Command

python -c "from pypdf import PdfReader; p='/tmp/workspace/attachments/28839604-0248-42f6-8057-0ee7a14cfabb/PRE ECLAMPSIA GEN SEM 1-compressed.pdf'; r=PdfReader(p); print('PAGES',len(r.pages)); [print('\\n---PAGE',i+1,'---\\n'+(page.extract_text() or '')[:5000]) for i,page in enumerate(r.pages)]"

Finding Sources
Finding Sources
I reviewed your 131-page PDF. The presentation has very good depth in pathogenesis, organ involvement, HELLP syndrome, eclampsia, and acute management. However, for an international-level PG seminar, it needs a clearer academic structure and several important missing sections.

Priority topics to add

1. Clear seminar objectives

Add this immediately after the title slide.
Suggested objectives
  • Define and classify hypertensive disorders of pregnancy.
  • Explain current understanding of pre-eclampsia pathogenesis.
  • Discuss prediction, prevention, diagnosis, surveillance, and management.
  • Compare major international guidelines.
  • Address maternal and neonatal outcomes, postpartum care, and long-term cardiovascular risk.

2. Epidemiology and global burden

Your presentation states incidence, but it lacks a focused global public-health slide.
Include:
  • Global prevalence: approximately 2% to 8% of pregnancies.
  • Contribution to maternal mortality, especially in low- and middle-income countries.
  • Burden of prematurity, fetal growth restriction, stillbirth, ICU admission, and healthcare costs.
  • Indian burden, if reliable institutional or national data are available.
  • Sustainable Development Goal relevance: preventing avoidable maternal and perinatal mortality.
The WHO overview supports including pre-eclampsia as a major global maternal and newborn health problem.

3. Correct BP measurement technique

This is a frequently asked viva and seminar question, but is missing.
Add a slide on:
  • Appropriate cuff size.
  • Seated position, back supported, feet on floor.
  • Arm supported at heart level.
  • Rest for at least 5 minutes before measurement.
  • Confirm BP with repeat reading.
  • Use validated devices for pregnancy.
  • Severe hypertension requires urgent confirmation and treatment, not delay.

4. Differential diagnosis of pre-eclampsia

This is an important missing academic section.
Include a comparison table between:
  • Chronic hypertension
  • Gestational hypertension
  • Pre-eclampsia
  • Superimposed pre-eclampsia
  • Acute fatty liver of pregnancy
  • HELLP syndrome
  • Thrombotic thrombocytopenic purpura
  • Hemolytic uremic syndrome
  • Systemic lupus erythematosus flare/lupus nephritis
  • Antiphospholipid syndrome
  • Chronic kidney disease
  • Viral hepatitis
  • Primary neurological disease in headache/seizures
Use discriminating features: gestation, hypertension, proteinuria, platelets, liver enzymes, bilirubin, glucose, creatinine, hemolysis, ADAMTS13 where relevant, and postpartum course.

5. Prevention of pre-eclampsia

This is the largest missing clinical topic. Your slides discuss prediction but do not adequately cover evidence-based prevention.
Add:
  • Low-dose aspirin for women at high risk, started early in pregnancy, ideally before 16 weeks.
  • Dose varies by guideline and local protocol. State your institutional policy and avoid presenting one dose as universal.
  • Calcium supplementation for women/populations with low dietary calcium intake.
  • Preconception optimization of obesity, chronic hypertension, diabetes, renal disease, and autoimmune disease.
  • What is not recommended routinely: antioxidants, vitamins C/E, salt restriction, bed rest, prophylactic diuretics, heparin without another indication.
This will significantly improve the international relevance of the seminar.

6. Maternal and fetal complications as one consolidated slide

Complications are described throughout your pathogenesis slides but should be summarized clearly.
Maternal
  • Eclampsia
  • HELLP syndrome
  • Acute kidney injury
  • Pulmonary edema
  • Stroke/intracranial hemorrhage
  • Disseminated intravascular coagulation
  • Placental abruption
  • Liver hematoma or rupture
  • Maternal death
Fetal and neonatal
  • Fetal growth restriction
  • Oligohydramnios
  • Prematurity, including iatrogenic prematurity
  • Stillbirth
  • Hypoxia/acidemia
  • NICU admission
  • Long-term adverse cardiometabolic outcomes

7. Fetal surveillance in pre-eclampsia

You mention Doppler and CTG, but a structured practical slide is needed.
Include:
  • Maternal fetal-movement awareness.
  • Serial fetal growth assessment.
  • Amniotic-fluid assessment.
  • Umbilical artery Doppler.
  • Middle cerebral artery and ductus venosus Doppler when early severe FGR is suspected and expertise is available.
  • CTG/non-stress test and biophysical profile where indicated.
  • Indications for delivery due to fetal compromise.

8. Delivery timing table

You have a delivery algorithm, but a single clean evidence-based table will be easier for the audience.
Clinical scenarioSuggested delivery plan
Gestational hypertension or pre-eclampsia without severe featuresDelivery at 37 weeks
Pre-eclampsia with severe features at or beyond 34 weeksStabilize mother and deliver
Severe disease before 34 weeksExpectant management only in selected stable women at tertiary center
Any gestation with uncontrolled severe hypertension, eclampsia, pulmonary edema, abruption, DIC, worsening HELLP, maternal deterioration, fetal death, or non-reassuring fetal statusStabilize and deliver
Clearly state that timing is individualized and follows local protocol. The ACOG practice bulletin and ISSHP guideline page are appropriate references.

9. A separate section on biomarkers: clinical usefulness and limitations

You cover sFlt-1/PlGF very well mechanistically, but the practical interpretation is incomplete.
Add:
  • Role of PlGF and sFlt-1/PlGF ratio mainly as an adjunct in suspected preterm pre-eclampsia.
  • Their value in ruling out short-term progression in selected settings.
  • They do not replace clinical assessment, BP measurement, laboratory evaluation, or fetal surveillance.
  • Cutoffs are assay-specific and depend on guideline and laboratory platform.
  • Availability and cost remain limiting factors in many Indian and low-resource settings.

10. Postpartum pre-eclampsia and delayed postpartum eclampsia

You discuss postpartum monitoring but should add this as a separate topic.
Include:
  • New-onset hypertension, headache, visual symptoms, dyspnea, epigastric pain, or seizures can occur after delivery.
  • Risk remains high in the first week postpartum, but disease may present later.
  • Postpartum warning signs requiring immediate evaluation.
  • Breastfeeding-compatible antihypertensives.
  • Avoidance of methyldopa postpartum due to depression risk.
  • Follow-up BP plan before discharge and within 7 to 10 days, earlier after severe hypertension.

11. Recurrence risk and long-term health consequences

This deserves 2 dedicated slides, not only a brief sentence.
Future pregnancy
  • Recurrence depends on severity, gestational age at onset, chronic hypertension, renal disease, obesity, and autoimmune disease.
  • Early-onset or severe disease has higher recurrence risk.
  • Preconception counseling and early booking are needed.
Long-term maternal health
  • Higher lifetime risk of chronic hypertension.
  • Ischemic heart disease and stroke.
  • Chronic kidney disease.
  • Diabetes and metabolic disease.
  • Need for annual BP, glycemic/metabolic, renal, and cardiovascular risk assessment.
Your presentation should emphasize that pre-eclampsia is not only an obstetric event but also a marker of future vascular disease.

12. Low-resource and Indian setting management

For an international seminar, this section will distinguish your presentation.
Add:
  • Early ANC registration and risk stratification.
  • BP screening at every antenatal contact.
  • Community recognition of warning signs.
  • Referral pathways for severe hypertension/eclampsia.
  • Magnesium sulfate availability and Pritchard regimen in settings without infusion pumps.
  • Blood products, ICU/HDU, neonatal services, and timely transfer to higher centres.
  • Importance of audit of eclampsia, maternal near-miss, and maternal death.

13. Case-based discussion

Add one clinical case near the end, followed by audience questions.
Example A 27-year-old primigravida at 31+4 weeks has BP 170/112 mmHg, headache, epigastric pain, platelets 92,000/µL, AST 110 U/L, creatinine 1.2 mg/dL, and fetal growth restriction with absent end-diastolic flow.
Ask:
  1. What is the diagnosis?
  2. What are the immediate steps?
  3. Which investigations are urgent?
  4. Is expectant management appropriate?
  5. What is the route and timing of delivery?
  6. What postpartum monitoring is needed?
This will demonstrate clinical decision-making to professors and subject experts.

14. Key take-home messages

End with a concise slide of 5 to 6 points:
  1. Pre-eclampsia is a placental disease with systemic maternal endothelial dysfunction.
  2. Proteinuria is not essential for diagnosis.
  3. Severe hypertension requires urgent treatment.
  4. Magnesium sulfate prevents and treats eclamptic seizures.
  5. Delivery is the definitive treatment, but timing balances maternal and fetal risks.
  6. Women need lifelong cardiovascular and renal risk follow-up.

Important corrections needed in the current slides

A. Remove all blank and template slides

There are many blank pages, including approximately slides/pages 9-14, 22, 24, 29, 36-41, 45-49, 55-58, 64-71, 74-76, 78-79, 84, 99-106, and 108-113.
Pages 122-131 contain “Lorem ipsum” placeholder text. These must be deleted before presentation. Leaving them in an international seminar will appear unprofessional.

B. Add a proper table of contents

Page 2 says “CONTENTS” but has no content. Add a clean, numbered outline.

C. Do not use “mild pre-eclampsia”

Use:
  • “Pre-eclampsia without severe features”
  • “Pre-eclampsia with severe features”
This is the preferred modern terminology.

D. Remove outdated diagnostic concepts on slide 44

Avoid using:
  • Relative rise of BP by 30/15 mmHg
  • MAP increase as a diagnostic criterion
  • Edema as a diagnostic criterion
Current diagnosis depends on new-onset hypertension after 20 weeks plus proteinuria and/or maternal organ dysfunction or uteroplacental dysfunction. The WHO diagnostic summary reflects the central role of hypertension with proteinuria or end-organ involvement.

E. Do not grade disease severity by amount of proteinuria

Proteinuria amount does not define severe features and should not determine timing of delivery.

F. Check all doses and thresholds against your hospital protocol

Especially:
  • Aspirin dose and duration.
  • sFlt-1/PlGF ratio thresholds.
  • Antihypertensive doses.
  • Magnesium sulfate regimen.
  • Postpartum antihypertensive stopping criteria.
  • HELLP steroid statements.
Do not state that corticosteroids are routinely used to improve maternal platelet count in HELLP syndrome. Antenatal corticosteroids are primarily for fetal lung maturation when preterm delivery is anticipated.

Recommended final sequence for a polished seminar

  1. Title
  2. Objectives
  3. Global and Indian burden
  4. Definitions and classification
  5. Risk factors
  6. Pathogenesis
  7. Early-onset versus late-onset disease
  8. Clinical features and warning symptoms
  9. Diagnosis and correct BP technique
  10. Investigations
  11. Differential diagnosis
  12. Prediction and biomarkers
  13. Prevention: aspirin and calcium
  14. Maternal complications
  15. Fetal complications and surveillance
  16. Management principles
  17. Acute severe hypertension
  18. Magnesium sulfate
  19. Timing and mode of delivery
  20. HELLP syndrome
  21. Eclampsia
  22. Intrapartum and postpartum care
  23. Recurrence and long-term cardiovascular/renal risk
  24. Low-resource/Indian context
  25. Recent advances and research gaps
  26. Clinical case
  27. Take-home messages
  28. References
  29. Thank you

Final advice

Your content is currently too long and repetitive for a seminar. Reduce it from 131 pages to approximately 55 to 70 high-quality slides. Keep the excellent pathophysiology content, but shorten repeated mechanisms and make space for prevention, differential diagnosis, postpartum disease, long-term risk, and guideline-based clinical decision-making.
This is a shared conversation. Sign in to Orris to start your own chat.